Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

Prognostic Biomarkers for Melanoma Immunotherapy

(2020) Christopher G. Twitty et al.   Current Oncology Reports

DNA Damage Response and Immune Defense

(2020) Claudia Nastasi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

(2020) Caroline Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma

(2020) Takeshi Fukumoto et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine

(2019) Zay Yar Oo et al.   Molecular Oncology

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

(2019) Kalindi Parmar et al.   CLINICAL CANCER RESEARCH

Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.

(2019) Triparna Sen et al.   Journal of Thoracic Oncology

STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity

(2019) Rana Falahat et al.   Cancer Immunology Research

Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor

(2019) Sourav Paul et al.   Journal for ImmunoTherapy of Cancer

Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer

(2019) Nazareth et al.   Cancers

Melanoma mutations modify melanocyte dynamics in co-culture with keratinocytes or fibroblasts

(2019) Dubravka Škalamera et al.   JOURNAL OF CELL SCIENCE

The interferon stimulated gene 20 protein (ISG20) is an innate defense antiviral factor that discriminates self versus non-self translation

(2019) Nannan Wu et al.   PLoS Pathogens

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

(2019) Dan A. Erkes et al.   Cancer Discovery

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

(2018) A Italiano et al.   ANNALS OF ONCOLOGY

Cytosolic DNA Sensing in Organismal Tumor Control

(2018) Claire Vanpouille-Box et al.   CANCER CELL

The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?

(2018) Teizo Yoshimura   Cellular & Molecular Immunology

Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 InhibitorsIn Vivo

(2018) Zay Yar Oo et al.   CLINICAL CANCER RESEARCH

The role of CXCL12 in tumor microenvironment

(2018) Wenfang Meng et al.   GENE

The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer

(2018) Tuo Li et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

(2018) Jung-Min Lee et al.   LANCET ONCOLOGY

ZBP1: Innate Sensor Regulating Cell Death and Inflammation

(2018) Teneema Kuriakose et al.   TRENDS IN IMMUNOLOGY

Crucial biological functions of CCL7 in cancer

(2018) Yangyang Liu et al.   PeerJ

Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target

(2018) Muhammad Zaeem Noman et al.   OncoImmunology

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation

(2018) Frank P. Vendetti et al.   JOURNAL OF CLINICAL INVESTIGATION

UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model

(2017) Jake Wang et al.   Pigment Cell & Melanoma Research

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma

(2017) Manuel Fankhauser et al.   Science Translational Medicine

Natural Killer T Cells in Cancer Immunotherapy

(2017) Shiny Nair et al.   Frontiers in Immunology

Chemotherapy and immunotherapy: mapping the road ahead

(2016) Alistair M Cook et al.   CURRENT OPINION IN IMMUNOLOGY

Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition

(2016) Peter Kar Han Lau et al.   CURRENT OPINION IN IMMUNOLOGY

Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

(2016) Emiliano Calvo et al.   ONCOLOGY

The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations

(2016) Katrina Meeth et al.   Pigment Cell & Melanoma Research

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

(2015) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

The Chemokine System in Innate Immunity

(2015) Caroline L. Sokol et al.   Cold Spring Harbor Perspectives in Biology

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

TGF-β Activation and Function in Immunity

(2013) Mark A. Travis et al.   Annual Review of Immunology

Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells

(2013) Beatrice Ondondo et al.   Frontiers in Immunology

Tumor-Derived Chemokine CCL5 Enhances TGF- -Mediated Killing of CD8+ T Cells in Colon Cancer by T-Regulatory Cells

(2012) L.-Y. Chang et al.   CANCER RESEARCH

A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress

(2012) K Brooks et al.   ONCOGENE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Identification of Regulatory Foxp3+ Invariant NKT Cells Induced by TGF- 

(2010) M. Monteiro et al.   JOURNAL OF IMMUNOLOGY